<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208790</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-OPML</org_study_id>
    <nct_id>NCT03208790</nct_id>
  </id_info>
  <brief_title>Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.</brief_title>
  <official_title>Clinical And Immunohistochemical Evaluation Of The Cancer Chemopreventive Effect Of Thymoquinone Compared To A Placebo On Oral Potentially Malignant Lesions Among An Egyptian Population : A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present randomized, controlled, parallel-grouped trial includes 48 patients (aged 18 to&#xD;
      75 years) suffering from oral potential premalignant lesions. Patients will be randomly&#xD;
      assigned into 3 equal groups: Group A: Nigella Sativa buccal tablets group 10mg Group B:&#xD;
      Nigella Sativa buccal tablets 5 mg Group C:Control group (placebo)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present randomized, controlled, parallel-grouped trial included 48 patients (aged 18 to&#xD;
      75 years) suffering from oral potentially premalignant lesions. Patients were randomly&#xD;
      assigned into 3 equal groups: Group A: Nigella Sativa buccal tablets group 10mg Group B:&#xD;
      Nigella Sativa buccal tablets 5 mg Group C:Control group (placebo)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2017</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical response</measure>
    <time_frame>baseline</time_frame>
    <description>dimension of the lesion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical response</measure>
    <time_frame>3 months</time_frame>
    <description>dimension of the lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular evidence of malignant transformation</measure>
    <time_frame>baseline</time_frame>
    <description>Immunohistochemical analysis using specific markers for cell proliferation(ki67)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular evidence of malignant transformation</measure>
    <time_frame>3 months</time_frame>
    <description>Immunohistochemical analysis using specific markers for cell proliferation(ki67)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular evidence of malignant transformation</measure>
    <time_frame>baseline</time_frame>
    <description>Immunohistochemical analysis using specific markers for apoptosis(caspase3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular evidence of malignant transformation</measure>
    <time_frame>3 months</time_frame>
    <description>Immunohistochemical analysis using specific markers for apoptosis(caspase3)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Premalignant Lesion</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with oral premalignant lesions will receive Nigella sativa buccal tablets 10mg for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with oral premalignant lesions will receive Nigella sativa buccal tablets 5mg for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients with oral premalignant lesions will receive placebo buccal tablets for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nigella sativa buccal tablets 10mg</intervention_name>
    <description>thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Nigella Sativa</other_name>
    <other_name>thymoquinone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nigella sativa buccal tablets 5mg</intervention_name>
    <description>thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Nigella Sativa</other_name>
    <other_name>thymoquinone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo buccal tablets</intervention_name>
    <description>capsules with the same color and form as the active ones but without active ingredient will be given to the patients</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with age range 18-75 years.&#xD;
&#xD;
          -  Patients with any known potentially malignant lesion confirmed histologically and&#xD;
             clinically.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with systemic illness.&#xD;
&#xD;
          -  Patients received previous treatment for the condition.&#xD;
&#xD;
          -  Current malignancy.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Hypersensitivity to the intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatheya Zahran</last_name>
    <role>Study Chair</role>
    <affiliation>Professor of Oral Medicine and Periodontology, Faculty of Oral and Dental Medicine, Cairo University.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Basma Abdelalim</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer of Oral Medicine and Periodontology, Faculty of Oral and Dental Medicine, Cairo University.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Dentistry</name>
      <address>
        <city>Cairo</city>
        <zip>11553</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Singh M, Krishanappa R, Bagewadi A, Keluskar V. Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncol. 2004 Jul;40(6):591-6.</citation>
    <PMID>15063387</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>April 17, 2021</last_update_submitted>
  <last_update_submitted_qc>April 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ghada Nabil</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

